{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:08:08Z","timestamp":1789600088816,"version":"build-2803163510"},"reference-count":29,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Prolactinomas are the most common functional pituitary adenomas, leading to an\n                    increased secretion of prolactin. The symptoms vary and include symptomatic as\n                    well as asymptomatic courses. Symptoms are mainly caused by hyperprolactinemia\n                    leading to a suppression of the hypothalamic\u2013pituitary\u2013gonadal axis. For\n                    individual therapy, planning the knowledge of influencing factors and disease\n                    progression is essential. Our goal was to examine the time period as well as the\n                    role of other influencing factors until the hypothalamic\u2013pituitary\u2013gonadal axis\n                    is normalized under cabergoline-therapy. We retrospectively analyzed the data of\n                    patients who were treated at Amedes in Hamburg between 2013 and 2023 from\n                    diagnosis to remission. Among initially 410 patients, 66 patients fulfilled all\n                    inclusion criteria. This large discrepancy is due to the fact that many patients\n                    had already started therapy with cabergoline before their initial endocrinology\n                    consultation. As a result, we lacked relevant information on baseline prolactin\n                    levels. Diagnosis of the suppressed hypothalamic\u2013pituitary\u2013gonadal axis was made\n                    by measuring diminished serum concentrations of luteinizing hormone (women:\n                    follicular phase&lt;2.4 mIU\/mL, ovulation phase&lt;14.0 mIU\/mL, luteal\n                    phase&lt;1.0 mIU\/mL, and postmenopause&lt;7.7 mIU\/mL; men:&lt;1.7 mIU\/mL),\n                    follicle stimulating hormone (women: follicular phase&lt;3.5 mIU\/mL, ovulation\n                    phase&lt;4.7 mIU\/mL, luteal phase&lt;1.7 mIU\/mL, and postmenopause&lt;25.8\n                    mIU\/mL; men&lt;1.5 mIU\/mL), estradiol (women:&lt;30.9 pg\/mL) or testosterone\n                    (men: 20\u201349 y&lt;2.49 ng\/mL, from 50 y&lt;1.93 ng\/mL). We examined the average\n                    time interval until normalization of these concentrations under cabergoline\n                    therapy and assessed whether there was a significant correlation between this\n                    time interval and other influencing factors. The mean duration until\n                    normalization of the hypothalamic\u2013pituitary\u2013gonadal axis under cabergoline\n                    therapy was 82 days. The statistical analysis showed a significant correlation\n                    between this duration and initial prolactin levels, as well as gender and age.\n                    Thus, patients with higher initial prolactin levels, older patients, and men had\n                    longer treatment durations. There was no correlation between time period and\n                    adenoma size, cabergoline dosage, comedication and accompanying diseases.<\/jats:p>","DOI":"10.1055\/a-2886-2899","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:10:35Z","timestamp":1780096235000},"page":"304-310","source":"Crossref","is-referenced-by-count":0,"title":["Recovery of the Gonadal Axis in Patients with\n                    Prolactinomas"],"prefix":"10.1055","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8256-3887","authenticated-orcid":false,"given":"Joob Ruben","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Asklepios Klinik Altona, Germany","place":["Hamburg"],"department":["Department of Radiology and Neuroradiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nader-M\u00fcller","sequence":"additional","affiliation":[{"name":"amedes MVZ Hamburg GmbH, Germany","place":["Hamburg"],"department":["Department of Fertility, Prenatal Medicine, Endocrinology, and\n                    Osteology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina","family":"Bullmann","sequence":"additional","affiliation":[{"name":"amedes MVZ Hamburg GmbH, Germany","place":["Hamburg"],"department":["Department of Fertility, Prenatal Medicine, Endocrinology, and\n                    Osteology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Shahla","sequence":"additional","affiliation":[{"name":"Duke University, North Carolina, United States","place":["Durham"],"department":["Department of Endocrinology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Harbeck","sequence":"additional","affiliation":[{"name":"University Medical Center\n                    Hamburg-Eppendorf, HH, Germany","place":["Hamburg"],"department":["Department of Rheumatology, Nephrology and Endocrinology"]},{"name":"Endokrinologikum Kiel, Germany","place":["Kiel"],"department":["Department of Endocrinology and Osteology"]},{"name":"Brandenburg Medical School, Germany","place":["Neuruppin"],"department":["Section Endocrinology\/Diabetology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: The old and the\n                    new","volume":"33","author":"P Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"ref2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: A Pituitary\n                    society international consensus statement","volume":"19","author":"S Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ecl.2014.11.003","article-title":"Prolactinomas","volume":"44","author":"A Glezer","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"113755","DOI":"10.1016\/j.ygcen.2021.113755","article-title":"Kobayashi Award 2019: The neuroendocrine regulation of the mammalian\n                    reproduction","volume":"315","author":"H Tsukamura","year":"2022","journal-title":"Gen Comp Endocrinol"},{"issue":"05","key":"ref5","first-page":"648","article-title":"Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine\n                    features and therapeutic responses in 56 cases","volume":"62","author":"F G\u00f3mez","year":"1977","journal-title":"Am J Med"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/edrv-1-3-295","article-title":"Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive\n                    study","volume":"1","author":"J Schlechte","year":"1980","journal-title":"Endocr Rev"},{"issue":"1\/2","key":"ref7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","article-title":"Hyperprolactinemia in men: clinical and biochemical features and response to\n                    treatment","volume":"20","author":"M De Rosa","year":"2003","journal-title":"Endocrine"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An endocrine society clinical\n                    practice guideline","volume":"96","author":"S Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","article-title":"Long-term remission following withdrawal of dopamine agonist therapy in subjects\n                    with microprolactinomas","volume":"63","author":"M Biswas","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"21","key":"ref10","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral\n                    hyperprolactinemia","volume":"349","author":"A Colao","year":"2003","journal-title":"N Engl J Med"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists:\n                    systematic review and meta-analysis","volume":"95","author":"O M Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline\n                    therapy","volume":"94","author":"J Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11102-019-00987-3","article-title":"Dopamine agonist resistant prolactinomas: Any alternative medical\n                    treatment?","volume":"23","author":"P Souteiro","year":"2020","journal-title":"Pituitary"},{"issue":"06","key":"ref14","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","article-title":"Predicting hypogonadotropic hypogonadism persistence in male\n                    macroprolactinoma","volume":"25","author":"Y Rudman","year":"2022","journal-title":"Pituitary"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","article-title":"Recovery from hypogonadism in men with prolactinoma treated with dopamine\n                    agonists","volume":"27","author":"S M Constantinescu","year":"2024","journal-title":"Pituitary"},{"issue":"09","key":"ref16","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"J J Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1025377816769","article-title":"Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism\n                    at diagnosis. II. Proportion of cases exhibiting recovery of pituitary\n                    function","volume":"5","author":"L Sibal","year":"2002","journal-title":"Pituitary"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","article-title":"The treatment with cabergoline for 24 month normalizes the quality of seminal\n                    fluid in hyperprolactinaemic males","volume":"64","author":"M De Rosa","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"03","key":"ref19","first-page":"314","article-title":"Recovery pattern of hypothalamo-pituitary-testicular axis in patients with\n                    macroprolactinomas after treatment with cabergoline","volume":"134","author":"R Walia","year":"2011","journal-title":"Indian J Med Res"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/cen.12124","article-title":"Does hypopituitarism recover when macroprolactinomas are treated with\n                    cabergoline?","volume":"79","author":"N Karavitaki","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis\n                    suppression in male macroprolactinomas with normoprolactinemia on\n                    cabergoline","volume":"105","author":"M Sehemby","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s11102-022-01242-y","article-title":"Proportion and predictors of Hypogonadism Recovery in Men with\n                    Macroprolactinomas treated with dopamine agonists","volume":"25","author":"K M Al Dahmani","year":"2022","journal-title":"Pituitary."},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month\n                    treatment on prolactin levels, tumor mass, recovery of pituitary function, and\n                    semen analysis","volume":"89","author":"A Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"ref24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of\n                    hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"J Webster","year":"1994","journal-title":"N Engl J Med"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1590\/2359-3997000000230","article-title":"Interactions between prolactin and kisspeptin to control reproduction","volume":"60","author":"J Donato","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/ijms25041976","article-title":"Current Insights in prolactin signaling and ovulatory function","volume":"25","author":"D Szukiewicz","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"D Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.1992.tb01485.x","article-title":"Dose-dependent suppression of serum prolactin by cabergoline in\n                    hyperprolactinaemia: a placebo controlled, double blind, multicentre study.\n                    European Multicentre cabergoline dose-finding study group","volume":"37","author":"J Webster","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","article-title":"Management of medically refractory prolactinoma","volume":"117","author":"M E Molitch","year":"2014","journal-title":"J Neurooncol"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2886-2899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:31:38Z","timestamp":1789597898000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2886-2899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":29,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,16]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2886-2899","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,29]]},"published":{"date-parts":[[2026,5,29]]}}}